These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 12091601)

  • 1. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy.
    Goodnough LT
    Nephrol Dial Transplant; 2002; 17 Suppl 5():14-8. PubMed ID: 12091601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjunctive therapy in anaemia management.
    Hörl WH
    Nephrol Dial Transplant; 2002; 17 Suppl 5():56-9. PubMed ID: 12091609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
    Eschbach JW; Varma A; Stivelman JC
    Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload.
    Tarng DC; Huang TP; Chen TW; Yang WC
    Kidney Int Suppl; 1999 Mar; 69():S107-18. PubMed ID: 10084294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
    Ahluwalia N; Skikne BS; Savin V; Chonko A
    Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
    Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
    Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease.
    Barosi G; Merlo C; Palestra P; Liberato NL; Guarnone R; Di Dio F; Piazza V; Salvadeo A
    Acta Haematol; 1993; 90(1):13-8. PubMed ID: 8237268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron management during treatment with recombinant human erythropoietin in chronic renal failure.
    Watson A
    J Clin Pharmacol; 1993 Dec; 33(12):1134-8. PubMed ID: 8126248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship of erythropoietin and iron metabolism to red blood cell production in humans.
    Adamson JW
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):9-15. PubMed ID: 8202725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin.
    Beguin Y; Loo M; R'Zik S; Sautois B; Lejeune F; Rorive G; Fillet G
    Br J Haematol; 1995 Jan; 89(1):17-23. PubMed ID: 7833259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant erythropoietin in autologous blood donation].
    von Bormann B; Weidler B; Friedrich M; von Andrian-Werburg H
    Anaesthesist; 1991 Jul; 40(7):386-90. PubMed ID: 1928712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of human recombinant erythropoietin in oncologic surgery].
    Mercuriali F
    Tumori; 1997; 83(4 Suppl 2):S16-9. PubMed ID: 9487379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin and renal transplantation.
    Muirhead N
    Kidney Int Suppl; 1999 Mar; 69():S86-92. PubMed ID: 10084292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaemia of critical illness-- implications for understanding and treating rHuEPO resistance.
    Eckardt KU
    Nephrol Dial Transplant; 2002; 17 Suppl 5():48-55. PubMed ID: 12091608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations for optimal iron use for anemia due to chronic kidney disease.
    Hudson JQ; Comstock TJ
    Clin Ther; 2001 Oct; 23(10):1637-71. PubMed ID: 11726002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
    Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
    Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients.
    Hung SC; Tung TY; Yang CS; Tarng DC
    Am J Kidney Dis; 2005 Jun; 45(6):1073-83. PubMed ID: 15957137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased iron absorption during autologous blood donation supported by recombinant human erythropoietin therapy.
    Bovy C; Baudoux E; Salmon JP; Beguin Y
    Transfusion; 2006 Sep; 46(9):1616-23. PubMed ID: 16965592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin treatment in haemodialysis patients with iron overload.
    el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB
    Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.